Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- PMDA Reviewing Safety Risks for Ivermectin, Xeljanz
September 13, 2021
- Causal Link between Deaths and Recalled Batch of Moderna Jab “Indeterminable”
September 13, 2021
- MHLW to Promptly Seek Expert Panel Discussion on Booster Shots: Minister
September 13, 2021
- Japan Should Arrange Boosters Immediately, Mix-and-Match Doses Too: LDP
September 10, 2021
- Regional Governors Club Urges Early Conclusion on HPV Vaccines
September 10, 2021
- COVID-19 Antibody Cocktail Given to 13,000 in Japan by August-End: MHLW
September 10, 2021
- Cabinet Counselor Koichi Ando Tapped as MHLW Economic Affairs Chief
September 8, 2021
- MHLW to Fund Avigan Program, COVID-19 Drugs from AZ, Shionogi
September 8, 2021
- Japan Strikes Deal for 150 Million Novavax Vaccine Doses, Supply Could Start Early Next Year
September 7, 2021
- Astellas’ Padcev, Pfizer’s JAK Inhibitor, AZ’s Lupus Drug Clear PAFSC Panel
September 7, 2021
- Pfizer Vaccine Imports Set to Be Completed in October: Minister
September 7, 2021
- MHLW Panel Backs Takeda’s Cell Therapy Darvadstrocel for Complex Anal Fistulas in CD
September 7, 2021
- Drug Makers Should Conduct Joint Inspections at Contract Manufacturers to Prevent GMP Violations: Expert
September 7, 2021
- Entresto Clears MHLW Panel with Strings Attached, It’s Not a 1st Choice Drug
September 6, 2021
- Japan Govt to Accelerate Discussion on Specific Growth Strategy
September 3, 2021
- Nationwide On-Site Inspections Identify GMP Issues at 9 Generic Plants: MHLW
September 3, 2021
- MHLW Panel to Review Entresto’s Hypertension Indication Again on September 3
September 3, 2021
- Healthcare Spending Totals 42.2 Trillion Yen in FY2020, Showing Record Drop of 1.4 Trillion Yen: MHLW
September 2, 2021
- LDP’s COVID-19 Headquarters Calls for Guidelines on Oral Steroid Administration to Patients Recuperating at Home
September 1, 2021
- Council to Discuss Resuming Active Recommendation of HPV Vaccines: Health Minister
September 1, 2021
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…